These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34098371)

  • 1. Prostate Imaging Reporting and Data System (PI-RADS): What the radiologists need to know?
    Razek AAKA; El-Diasty T; Elhendy A; Fahmy D; El-Adalany MA
    Clin Imaging; 2021 Nov; 79():183-200. PubMed ID: 34098371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
    J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study.
    Choi MH; Kim CK; Lee YJ; Jung SE
    AJR Am J Roentgenol; 2019 Apr; 212(4):839-846. PubMed ID: 30779662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the compliance with minimum acceptable technical parameters proposed by PI-RADS v2 guidelines in multiparametric prostate MRI acquisition in tertiary referral hospitals in the Republic of Turkey.
    Coşkun M; Sarp AF; Karasu Ş; Gelal MF; Türkbey B
    Diagn Interv Radiol; 2019 Nov; 25(6):421-427. PubMed ID: 31650967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI).
    Gatti M; Faletti R; Calleris G; Giglio J; Berzovini C; Gentile F; Marra G; Misischi F; Molinaro L; Bergamasco L; Gontero P; Papotti M; Fonio P
    Abdom Radiol (NY); 2019 May; 44(5):1883-1893. PubMed ID: 30788558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of dynamic contrast enhancement on diffusion weighted imaging score of 3 in prostate imaging reporting and data system version 2 of peripheral zone].
    Wang W; Shao ZH; Huang XH; Xu Y; Feng X; Wang PJ
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):1002-1006. PubMed ID: 32294857
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation.
    Israël B; Leest MV; Sedelaar M; Padhani AR; Zámecnik P; Barentsz JO
    Eur Urol; 2020 Apr; 77(4):469-480. PubMed ID: 31767492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic magnetic resonance imaging for primary prostate cancer evaluation: Diagnostic potential of a non-contrast-enhanced bi-parametric approach enhanced with relaxometry measurements.
    Arita Y; Akita H; Fujiwara H; Hashimoto M; Shigeta K; Kwee TC; Yoshida S; Kosaka T; Okuda S; Oya M; Jinzaki M
    Eur J Radiol Open; 2022; 9():100403. PubMed ID: 35242886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
    Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI-RADS Version 2: A Pictorial Update.
    Purysko AS; Rosenkrantz AB; Barentsz JO; Weinreb JC; Macura KJ
    Radiographics; 2016; 36(5):1354-72. PubMed ID: 27471952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
    Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
    Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media?
    Huebner NA; Korn S; Resch I; Grubmüller B; Gross T; Gale R; Kramer G; Poetsch N; Clauser P; Haitel A; Fajkovic H; Shariat SF; Baltzer PA
    Eur Radiol; 2021 Jun; 31(6):3754-3764. PubMed ID: 33263793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate imaging reporting and data system version 2 (PI-RADS v2): a pictorial review.
    Hassanzadeh E; Glazer DI; Dunne RM; Fennessy FM; Harisinghani MG; Tempany CM
    Abdom Radiol (NY); 2017 Jan; 42(1):278-289. PubMed ID: 27522352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?
    Junker D; Steinkohl F; Fritz V; Bektic J; Tokas T; Aigner F; Herrmann TRW; Rieger M; Nagele U
    World J Urol; 2019 Apr; 37(4):691-699. PubMed ID: 30078170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biparametric MRI of the prostate.
    Scialpi M; D'Andrea A; Martorana E; Malaspina CM; Aisa MC; Napoletano M; Orlandi E; Rondoni V; Scialpi P; Pacchiarini D; Palladino D; Dragone M; Di Renzo G; Simeone A; Bianchi G; Brunese L
    Turk J Urol; 2017 Dec; 43(4):401-409. PubMed ID: 29201499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate MRI based on PI-RADS version 2: how we review and report.
    Steiger P; Thoeny HC
    Cancer Imaging; 2016 Apr; 16():9. PubMed ID: 27067275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic accuracy of biparametric versus multiparametric prostate MRI: assessment of contrast benefit in clinical practice.
    Zawaideh JP; Sala E; Shaida N; Koo B; Warren AY; Carmisciano L; Saeb-Parsy K; Gnanapragasam VJ; Kastner C; Barrett T
    Eur Radiol; 2020 Jul; 30(7):4039-4049. PubMed ID: 32166495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility artifacts and PIRADS 3 lesions in prostatic MRI: how often is the dynamic contrast-enhance sequence necessary?
    Antunes N; Vas D; Sebastia C; Salvador R; Ribal MJ; Nicolau C
    Abdom Radiol (NY); 2021 Jul; 46(7):3401-3409. PubMed ID: 33683430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central zone lesions on magnetic resonance imaging: Should we be concerned?
    Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
    Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
    Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
    Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.